Bright Minds Biosciences Inc. · CSE:DRUG
Bright Minds Biosciences — Technical Presentation (January 2026)
36 slides from Bright Minds Biosciences's technical presentation, Jan 6, 2026
Slide 1: BREAKTHROUGH Study in Patients with Absence Seizures and DEE
BMB-101 BREAKTHROUGH Study in Patients with Absence Seizures and DEE //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// Phase 2 Topline Data January 6, 2026 NASDAQ: DRUG | BRIGHTMINDSBIO.COM
Slide 2: Disclaimer and Cautionary Note regarding Forward Looking Statements
Disclaimer and Cautionary Note regarding Forward Looking Statements This corporate presentation (this “Presentation”) of Bright Minds Biosciences Inc. constitute forward-looking information. Forward-looking information contained in matters; and (xxix) market competition, including the prices, produc
Slide 3: Event speakers
Event speakers Bright Minds Bio Participants Ian McDonald Stephen Collins, MD, Jan T. Pedersen, Alex Vasilkevich, MSc Chief Executive Officer, PhD PhD, MSc Chief Operating Officer Director Chief Medical Officer Chief Scientific Officer, Director NASDAQ: DRUG | BRIGHTMINDSBIO.COM 3
Slide 4: We Thank
We Thank Principal Investigators Trial And their outstanding teams Participants /////////////////////////////////////////////////////// /////////////////////////////////////////////////////// For your dedication For your courage and and expertise commitment This success would not have been possible
Slide 5: BREAKTHROUGH Study in Patients with Absence Seizures and DEE
BMB-101 BREAKTHROUGH Study in Patients with Absence Seizures and DEE /////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// Phase 2 Topline Data Ian McDonald Chief Executive Officer Bright Minds Biosciences NASDAQ: DRUG | BRIGHTMINDSBI
Slide 6: About BMB-101
About BMB-101 Highly selective 5-HT ////////////////////////////////////////////2C biased agonist with potential for improved efficacy in a chronic dosing paradigm Superior pharmacokinetics: linear kinetics throughout the dosing range //////////////////////////////////////////// Convenience of admin
Slide 7: BMB-101 demonstrates efficacy in drug resistant Absence Seizures and DEE
BMB-101 demonstrates efficacy in drug resistant Absence Seizures and DEE Absence Seizures DEE -73.1% -63.3% Median reduction of absence seizures ≥ 3s Median reduction in major motor seizures as measured by 24h EEG as measured by seizure diary DEE - Developmental and epileptic encephalopathy, EEG - E
Slide 8: Potentially best-in-class
Potentially best-in-class BMB-101 was safe and well tolerated in patients with Absence Seizures and DEE //////////////////////////////////////////// BMB-101 met both primary and secondary endpoints in Absence Seizures and DEE //////////////////////////////////////////// BMB-101 demonstrates a potent
Slide 9: BREAKTHROUGH Study in Patients with Absence Seizures and DEE
BMB-101 BREAKTHROUGH Study in Patients with Absence Seizures and DEE /////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// Phase 2 Topline Data Stephen Collins, MD, PhD Chief Medical Officer Bright Minds Biosciences NASDAQ: DRUG | BRI
Slide 10: BMB-101 Ph.2 study in adult patients with Absence Seizures or DEE
BMB-101 Ph.2 study in adult patients with Absence Seizures or DEE An Open-Label Phase 2 Study To Evaluate the Efficacy, Safety and Tolerability of BMB-101 in Adults Absence Seizures Arm DEE Arm Seizure frequency measured using 24h ambulatory EEG Seizure frequency measured by seizure diary Key entry
Slide 11: Highly refractory patients enrolled
Highly refractory patients enrolled Overall 24 Unmet need: Absence seizures • Failed mean 3.7 antiseizure treatments 15 Patient seizure burden: • Up to 606 seizures ≥3s duration per 24h DEE Unmet need: 9 • Failed mean 9.8 anti-seizure treatments, including fenfluramine • 7 LGS Real world clinical sc
Slide 12: Demographics
Demographics Absence Seizures DEE N=15 N=9 Age, mean (range) 30 (18-61) 30.1 (21-63) Sex 8M + 7F 3M + 6 F Weight, kg 84.5 (51-137.4) 66 (38-103.2) Number of concomitant Median 3 (1-7) Median 5 (3-7) anti-seizure treatments: Mean 3.1 Mean 4.9 Number of previously failed anti- Median 2 (0-16) Median 9
Slide 13: Patient disposition
Patient disposition Absence seizures DEE 17 Assessed for Eligibility 10 Assessed for Eligibility 15 Enrolled 9 Enrolled Discontinued Discontinued • Patient 1: Taste (related) – drug product formulation updated • Patient 1: Fluctuation in pre-existing behavior condition (possibly related) • Patient 2
Slide 14: BMB-101 in Absence Seizures
BMB-101 in Absence Seizures //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// Jan T. Pedersen, PhD, MSc Chief Scientific Officer Bright Minds Biosciences NASDAQ: DRUG | BRIGHTMINDSBIO.COM Refer to risk factors on Slide 2
Slide 15: What is an absence seizure?
What is an absence seizure? Absence seizure is defined as: • A distinct 3/s spike-and-wave discharge – an abnormal, and unique paroxysmal pattern of a high velocity spike followed by a slower dome shaped wave on the background of a normal EEG. • The 3/s spike-and-wave on EEG is clinically recognized
Slide 16: 5-HT2C Agonism constitutes specific mechanism for switching off absence seizures
5-HT2C Agonism constitutes specific mechanism for switching off absence seizures • Activation of 5-HT2C receptors in the cortico- Spike-wave discharge thalamo-cortical network switch off T-type (SWD) arises from Ca2+–dependent bursting in the cortico- thalamic circuit by depolarizing and oscillation
Slide 17: Limited treatment options represent significant opportunity for new branded agent
Limited treatment options represent significant opportunity for new branded agent in the Absence treatment paradigm Absence Seizure Management Ethosuximide Absence Seizures+ Absence Seizures only • Standard-of-care drug for CAE - only manages absence seizures (narrow-spectrum) • Associated with GI d
Slide 18: Topline Efficacy in Absence Seizures
Topline Efficacy in Absence Seizures //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// Stephen Collins, MD, PhD Chief Medical Officer Bright Minds Biosciences NASDAQ: DRUG | BRIGHTMINDSBIO.COM Refer to risk factors on Slide 2
Slide 19: First drug to demonstrate efficacy in Absence Seizures using objective 24h EEG measures
First drug to demonstrate efficacy in Absence Seizures using objective 24h EEG measures Seizure Burden – sum of individual seizures on EEG with a duration of ≥3s Absence Seizures • Patients with uncontrolled absence seizures • Seizures are counted based on 2x24h ambulatory EEG recordings done at bas
Slide 20: Robust reduction of Absence Seizures regardless of seizure duration
Robust reduction of Absence Seizures regardless of seizure duration Reduction in Absence Seizures ≥3s (N=11) ≥5s (N=9) ≥15s (N=4) -73.1% -74.4% -69.2% -74.7% -80.3% -81.8% Change in seizures Change in seizure burden N – number of patients with seizures of specific duration (≥3, ≥ 5, ≥ 15) NASDAQ: DR
Slide 21: Effects beyond seizures: Sleep
Effects beyond seizures: Sleep //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// NASDAQ: DRUG | BRIGHTMINDSBIO.COM Refer to risk factors on Slide 2
Slide 22: BMB-101 improves REM sleep in patients with Absence Seizures
BMB-101 improves REM sleep in patients with Absence Seizures without increasing sleep duration REM sleep duration, minutes Overall sleep duration, hours Increase in REM sleep 120 10 duration 106.7 9.1 8.9 100 8 80 6 +90% 60 56.2 4 40 2 20 0 0 Baseline BMB-101 Baseline BMB-101 Data available for N=11
Slide 23: Topline Efficacy in DEE
Topline Efficacy in DEE //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// NASDAQ: DRUG | BRIGHTMINDSBIO.COM Refer to risk factors on Slide 2
Slide 24: Significant decrease in seizures in highly refractory DEE patients
Significant decrease in seizures in highly refractory DEE patients Reduction in Major Motor Seizures LGS DEE other LGS* LGS Dravet* LGS LGS Rett 16.8% -60.3% -76.1% -47.3% -52.3% -73.3% -95.5% -100% Median reduction in Major Motor Seizures As measured by Seizure Diary Dravet patient previously faile
Slide 25: Highly refractory DEE subjects
Highly refractory DEE subjects Robust reduction of seizures in a real-world cohort Notable examples in highly Number of Previously Failed Antiseizure Therapies refractory population 3 Number of patients • The Dravet patient who failed fenfluramine due to efficacy demonstrated robust effect with BMB-
Slide 26: BMB-101 works well in harder to treat patients
BMB-101 works well in harder to treat patients DEE patients with 3 and more ASMs are less 8/9 DEE patients in BREAKTHROUGH trial were responsive to therapy, as seen from Bexicaserin on 4 or more antiseizure treatments and still PACIFIC trial (NCT05364021) demonstrated median >63% seizure reduction B
Slide 27: Topline Safety and Tolerability
Topline Safety and Tolerability //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// NASDAQ: DRUG | BRIGHTMINDSBIO.COM Refer to risk factors on Slide 2
Slide 28: BMB-101 is well-tolerated and safe in patients
BMB-101 is well-tolerated and safe in patients • Most of the TEAEs were mild (about 80%) • No significant changes on vital signs, labs or ECG • Three SAEs – all non drug-related: fractured shoulder with opiate-related drowsiness (2); and pneumonia (1) Relation Relation Adverse Total Total to drug to
Slide 29: Conclusion and Next Steps
Conclusion and Next Steps //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// NASDAQ: DRUG | BRIGHTMINDSBIO.COM Refer to risk factors on Slide 2
Slide 30: Conclusion
Conclusion Absence Seizures • BMB-101 was safe and well tolerated in patients with DEE and Absence Seizures -73.1% • BMB-101 met both primary and secondary endpoints in DEE and Absence Seizures DEE • BMB-101 demonstrates a potentially best-in-class profile for patients with refractory DEE and Absenc
Slide 31: Significant market in Absence Seizures and DEE
Significant market in Absence Seizures and DEE This is the first drug that demonstrated efficacy in validated endpoints in patients with DEE and Absence Seizures L REFRACTORY MARK – Opportunity in All DEEs – Opportunity with Absence TA ET TO Typical Absence Seizures All DEE Refractory Market All DEE
Slide 32: Comparison to peers
Comparison to peers BMB-101 Fenfluramine / Bexicaserin Cannabidiol / Epidiolex Drug Selective and Selective 5-HT2C agonist Fintepla Multimodal biased 5-HT2C agonist Non-selective 5-HT2C agonist Efficacy in LGS 60.3% 50.8% (PACIFIC) 26.5% (0.7 mg/kg)** 43.9% Ph.2a open-label trial (placebo 20.8%) 13%
Slide 33: Next steps
Next steps Bright Minds Biosciences will initiate global registrational studies in patients with DEE and //////////////////////////////////////////// Absence Seizures Bright Minds Biosciences will continue the analysis of the BREAKTHROUGH study and will //////////////////////////////////////////// r
Slide 34: Pipeline
Pipeline Rich and diverse portfolio in neurology and psychiatry with multiple programs Lead Indications Research Phase 1 Phase 2 Phase 3 5-HT2C agonists Registrational trials in DEE BMB-101 DEE Clinical Studies – Phase 2 topline announced Absence seizures Registrational trials in absence seizures BM
Slide 35: Q&A session
BMB-101 BREAKTHROUGH Study in Patients with Absence Seizures and DEE //////////////////////////////////////////////////////////////////////////////////////////////////////////////////////// Q&A session NASDAQ: DRUG | BRIGHTMINDSBIO.COM
Slide 36: Important Additional Information
Important Additional Information Bright Minds Biosciences Inc. (the “Issuer”) has filed a registration statement on Form F-3 (including a base prospectus (the “Base Prospectus”)) with the U.S. Securities and Exchange Commission (the “SEC”) (File No. 333-289851), and a preliminary prospectus suppleme
Bright Minds Biosciences — Technical Presentation (January 2026) on 6ix